厄洛替尼二线治疗化疗失败的晚期非小细胞肺癌的疗效观察OACSTPCD
Effect of Erlotinib as Second-Line Therapy on Advanced Non-Small Cell Lung Cancer Following Failure of Chemotherapy
目的：观察厄洛替尼治疗经一线化疗失败的晚期非小细胞肺癌（ NSCLC ）的临床疗效及安全性。方法经一线化疗方案治疗失败的晚期非小细胞肺癌（ NSCLC ）患者106例，分为实验组62例，对照组44例。两组患者均接受多西紫杉醇联合顺铂化疗方案治疗，实验组加用厄洛替尼。观察两组疗效及不良反应。结果实验组完全缓解（CR）4例、部分缓解（PR）24例、稳定（SD）28例、进展（PD）6例，对照组分别为0例、13例、14例、17例，实验组疗效优于对照组，差…查看全部>>
Objective To observe the efficacy and safety of erlotinib as the second-line therapy for advanced non small cell lung cancer(NSCLC) following failure of first-line chemotherapy.Methods One hundred and six patients with advanced NSCLC following failure of first-line chemotherapy were randomly divided into experimental group (n=62) and control group(n=44).Two groups were both treated with docetaxel combined with cisplatin chemotherapy ,while erlotinib was adde…查看全部>>
罗向晖;曹燕飞;陈耀华;吴昱;杨晔
陕西省人民医院胸外科，西安市 710068陕西省人民医院胸外科，西安市 710068陕西省人民医院胸外科，西安市 710068陕西省人民医院胸外科，西安市 710068陕西省人民医院胸外科，西安市 710068
医药卫生
非小细胞肺癌厄洛替尼二线治疗疗效
Non-small cell lung cancerErlotinibSecond-line therapyEfficacy
《广西医学》 2014 (8)
1096-1098,3
评论